Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Acute Psychological and Physiological Effects of Cannabigerol

NCT06638996 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to examine the acute effects of cannabigerol (CBG) on various psychological (e.g., anxiety, stress, mood, memory, impairment, intoxication, side effects) and physiological (blood pressure, cortisol, heart rate variability, electrodermal activity, pain tolerance, temperature) outcomes. Further, potential side effects of CBG (sleepiness/fatigue, dry mouth/eyes, increased appetite, and dizziness nausea) will be assessed. As such, the study is focused on better understanding some of the potentially beneficial and detrimental effects of CBG on humans.

Interventions

  • DIETARY_SUPPLEMENT CBG Intervention
  • OTHER Placebo Intervention

Study Locations (1)

Washington

  • Washington State University - Pullman Campus — Pullman

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2024-10-28
Est. Completion 2026-10-31
Phase NA

Sponsor

Washington State University

84 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06638996

The ClinicalTrials.gov registry entry for NCT06638996 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington State University, which has 84 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with No Disease or Condition is Being Studied appearing as the primary indexed condition, and to 2 interventions — of which CBG Intervention is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06638996 reports 1 study location spanning 1 distinct geographic area — top geographies include Washington. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06638996 about?

NCT06638996 is a clinical study titled "Acute Psychological and Physiological Effects of Cannabigerol". The purpose of this study is to examine the acute effects of cannabigerol (CBG) on various psychological (e.g., anxiety, stress, mood, memory, impairment, intoxication, side effects) and physiological (blood pressure, cortisol, heart rate variability, electrodermal activity, pain tolerance, temperat...

What is the current status of trial NCT06638996?

This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2024-10-28. Estimated completion is 2026-10-31.

What conditions does trial NCT06638996 study?

This clinical trial studies the following conditions: No Disease or Condition is Being Studied. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06638996?

The interventions under investigation include: CBG Intervention (DIETARY_SUPPLEMENT), Placebo Intervention (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06638996?

This trial is sponsored by Washington State University, which has 84 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06638996 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial